Core Viewpoint - Shanghai Taosheng Electronic Technology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, aiming to raise approximately 1.058 billion yuan [1] Company Overview - Taosheng Technology specializes in the semiconductor testing interface sector, providing critical testing hardware solutions for various stages of the semiconductor industry chain, including chip design, wafer manufacturing, and packaging testing [1] Financial Aspects - The company plans to raise around 1.058 billion yuan through its IPO [1]

Company Overview - Ruishi Chuangxin (Chongqing) Technology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board [1] - The company focuses on the research, design, manufacturing, and sales of radio frequency front-end modules and discrete devices [1] Business Objectives - Ruishi Chuangxin aims to raise approximately 809 million yuan through this IPO [1] - The funds will be allocated to the construction of the second phase of the MEMS device production base, the establishment of a research and development center, and to supplement working capital [1]

2025年12月30日，上交所官网显示，长鑫科技集团股份有限公司（简称：长鑫科技长鑫存储）科创板 IPO申请获受理，保荐机构为中国国际金融股份有限公司、中信建投证券股份有限公司，审计机构为德 勤华永会计师事务所（特殊普通合伙），律师事务所为上海市锦天城律师事务所。融资金额为295亿 元。 2025年12月30日，上交所官网显示，长鑫科技集团股份有限公司（简称：长鑫科技长鑫存储）科创板 IPO申请获受理，保荐机构为中国国际金融股份有限公司、中信建投证券股份有限公司，审计机构为德 勤华永会计师事务所（特殊普通合伙），律师事务所为上海市锦天城律师事务所。融资金额为295亿 元。 ...

Core Viewpoint - Dongfang Measurement and Control Technology Co., Ltd. (referred to as "Dongfang Measurement") has had its IPO application accepted on the Sci-Tech Innovation Board, but it faces significant historical funding issues, including a 23-year delayed capital contribution assessment and illegal debt contributions according to past company laws [1][2][17]. Financial Performance - Dongfang Measurement's main business involves providing intelligent online detection and analysis equipment for the non-ferrous metal mining sector and related services. The company reported revenues of CNY 603 million, CNY 521 million, CNY 567 million, and CNY 211 million for the years 2022-2024 and the first half of 2025, respectively. The net profit attributable to shareholders was CNY 93 million, CNY 75 million, CNY 73 million, and CNY 4 million for the same periods. The company experienced a decline in both revenue and net profit in 2023, with a slight revenue increase but no profit growth expected in 2024 [2][17]. Historical Funding Issues - Dongfang Measurement has a history of multiple funding irregularities, including shareholders failing to make timely contributions and using debt as a form of capital contribution without proper evaluation, which was prohibited by the company law at the time [2][5][20]. - The company completed its capital contributions late, with the initial shareholders not fulfilling their obligations until July 2002, despite being required to do so by June 1996 [3][18]. Recent Capital Increases - The company underwent three capital increases in 2022, with the last two occurring in September. The capital was raised from CNY 77.75 million to CNY 81.36 million and then to CNY 89.10 million by December 2022. The valuation increased significantly from approximately CNY 869 million to CNY 2.3 billion, a growth of about 165% [10][25]. Client Relationships and Valuation - Major clients, including Jiangxi Copper Group and Zijin Zijin, participated in the capital increases through their subsidiaries, which temporarily inflated Dongfang Measurement's valuation. However, this also comes with the risk of buyback agreements that could impose future financial obligations on the company if it fails to go public by the end of 2028 [11][26]. Research and Development Metrics - Dongfang Measurement's R&D personnel accounted for 23.84% of its total workforce, significantly lower than comparable companies such as Meiteng Technology (28.01%), Rongzhi Rixin (38.6%), and Tianma Zhikong (39.87%). The company's R&D expense ratio also fell below the industry average, with rates of 8.19%, 10.18%, 10.08%, and 12.03% for the years 2022-2024 and the first half of 2025, compared to the average rates of 10.59%, 12.28%, 11.31%, and 12.21% for its peers [12][28][30].

Core Viewpoint - Jiangsu Gaokai Precision Fluid Technology Co., Ltd. has reinitiated its IPO attempt on the Sci-Tech Innovation Board after a previous unsuccessful attempt four years ago, with the application now accepted by the Shanghai Stock Exchange [1] Company Overview - Gaokai Technology specializes in the research, development, production, and sales of key control components and related equipment in the precision fluid control sector [1] IPO Details - The company aims to raise approximately 1.5 billion yuan, which will be allocated to high-end semiconductor equipment component R&D and industrialization projects, R&D center construction, and to supplement working capital [1] - The previous IPO attempt was accepted on June 17, 2021, and entered the inquiry stage on July 7, 2021, but was terminated on December 13, 2021, after only six months in the queue [1]

Group 1 - The core viewpoint of the article is that Shiya Technology Co., Ltd. has submitted its IPO registration for the Sci-Tech Innovation Board, aiming to raise approximately 2.015 billion yuan for expansion and R&D projects [1] - Shiya Technology specializes in micro-display solutions, with its main product being silicon-based OLED micro-displays, and offers value-added services including strategic product development and optical systems [1] - The IPO process began with acceptance on June 26, 2025, followed by an inquiry phase on July 21, and approval on December 24 of the same year [1] Group 2 - The funds raised from the IPO will be allocated to the expansion of ultra-high-resolution silicon-based OLED micro-display production lines and the construction of a research and development center [1]

Core Viewpoint - Dongfang Measurement and Control Technology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, aiming to raise 1.1 billion yuan for various projects, despite facing declining revenues and profits in recent years [1][3]. Financial Performance - The company's revenue for the reporting periods (2022 to the first half of 2025) is projected to be 603.48 million yuan, 520.91 million yuan, 567.17 million yuan, and 210.77 million yuan, indicating a significant drop in 2023, with 2024 expected to show growth but still below 2022 levels [1]. - Net profit attributable to shareholders for the same periods is expected to be 92.53 million yuan, 74.78 million yuan, 73.09 million yuan, and only 4.30 million yuan in the first half of 2025, reflecting a continuous decline over the years [1]. - The gross profit margin for the main business is reported as 42.10%, 39.16%, 41.29%, and 37.91%, with the smart control system's gross margin showing significant fluctuations [1]. Accounts Receivable and Inventory - Accounts receivable have sharply increased, with balances of 317.01 million yuan, 282.41 million yuan, 359.14 million yuan, and 367.10 million yuan, representing 52.53%, 54.21%, 63.32%, and 87.09% of revenue respectively, indicating a concerning trend in collection efficiency [2]. - Inventory balances are reported as 337.35 million yuan, 338.40 million yuan, 300.06 million yuan, and 327.02 million yuan, with provisions for inventory impairment also noted, suggesting potential risks related to inventory valuation [2]. Related Party Transactions and Financial Ratios - The company has significant related party sales and purchases, with sales to related parties accounting for 4.93% and purchases for 2.89% in 2024, asserting that pricing is fair and does not harm the interests of non-related shareholders [3]. - Liquidity ratios show a current ratio of 1.82, 2.13, 2.25, and 2.25, and a quick ratio of 1.18, 1.29, 1.52, and 1.46, indicating an upward trend but still below industry peers [3]. - The debt-to-asset ratio has decreased from 48.92% to 36.48% over the reporting periods, although it remains higher than comparable companies in the industry [3]. Ownership Structure and Fundraising - The actual controllers of the company are Bao Liangqing and Bao Caiyi, holding 9.79% and 5.27% of shares respectively, with control over 87.18% of voting rights through various entities [3]. - The company plans to raise 1.1 billion yuan for projects related to smart online analysis instruments, equipment, control systems, and the establishment of a research and development center and sales service center [3].

Group 1 - The core point of the article is that Dandong Oriental Measurement and Control Technology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, aiming to raise approximately 1.1 billion yuan [1][1][1] - The company provides intelligent online detection and analysis equipment, intelligent control systems, and related services for various industries, including non-ferrous and ferrous metal mining, coal, cement, metallurgy, wind power, and petrochemicals [1][1][1] - The funds raised from the IPO will be used for the industrialization of intelligent online analysis instruments, equipment and control systems, the construction of a research and development center, and the establishment of a sales service center [1][1][1]

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has achieved profitability and is preparing for its IPO, representing a significant case under the fifth listing standard of the Sci-Tech Innovation Board for pharmaceutical companies [1][4]. Group 1: Company Developments - Beixin Life has registered its IPO as of December 18, 2023, and is focused on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [4]. - The company reported a revenue of 128 million yuan in Q1 2023, a year-on-year increase of 104.9%, and a net profit of 20.61 million yuan, marking a turnaround from previous losses [4]. - Other companies in the IPO queue include Hengrun Dabiotech and Sizerui, both of which have been in the process for over three years, with Hengrun Dabiotech's IPO currently on hold due to outdated financial data [7][8]. Group 2: Market Activity - As of December 25, 2023, there are eight pharmaceutical companies in the IPO queue under the fifth listing standard, with six companies having received acceptance this year [4][5]. - The reactivation of the fifth listing standard has revitalized the IPO market for pharmaceutical companies, with five unprofitable companies receiving acceptance this year [5]. - Among the eight companies, seven have already launched products, indicating a shift in the regulatory environment towards unprofitable pharmaceutical firms [9]. Group 3: Regulatory Environment - The regulatory focus for unprofitable pharmaceutical companies includes the robustness of technology, market potential, financial sustainability, and risk of delisting [10]. - The approval process for unprofitable companies emphasizes clinical value and commercial viability, with a strong emphasis on innovation and compliance [10].

Core Viewpoint - The upcoming IPO of Visionary Technology on December 24 has sparked significant controversy due to its financial performance and capital raising strategy, raising questions about its valuation and operational sustainability [1][13]. Group 1: Shareholding and Governance Issues - Visionary Technology, established on October 13, 2016, has its actual controller, Gu Tie, holding 61.79% of voting rights through special voting arrangements, which raises concerns about share stability during the IPO process [2]. - The company’s shareholding structure and pricing details have prompted market discussions, indicating potential governance issues [2]. Group 2: Financial Performance and Profitability - The company reported cumulative losses of 921 million yuan from 2022 to mid-2025, with an average annual loss of 129 million yuan since its inception, primarily due to high R&D expenditures [7]. - Revenue figures for 2022 to mid-2025 were 190 million yuan, 215 million yuan, 280 million yuan, and 150 million yuan, with a compound annual growth rate of approximately 21.27%, failing to meet the conventional growth indicators required for IPO [6][12]. - R&D expenses during the reporting period were 237 million yuan, 287 million yuan, 269 million yuan, and 121 million yuan, indicating that R&D investments exceeded annual revenues in 2022 and 2023, reflecting the long development cycle and high costs associated with silicon-based OLED technology [7]. Group 3: Capital Raising and Financial Position - As of June 30, 2025, the company held 1.565 billion yuan in cash and cash equivalents, which accounted for 36.64% of total assets, raising questions about the necessity of raising an additional 2.015 billion yuan [9]. - The proposed fundraising is intended for the expansion of high-resolution silicon-based OLED microdisplay production lines and R&D center construction, which aligns with core business expansion rather than a "crying poverty" narrative [12]. - The company’s debt-to-asset ratio was reported at 51.88%, slightly lower than its competitor BOE, indicating a strong debt repayment capability [12].